Overview

Combination Chemotherapy in Treating Children With Lymphoma

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have lymphoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Asparaginase
Cyclophosphamide
Cytarabine
Daunorubicin
Doxorubicin
Etoposide
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Methotrexate
Pegaspargase
Prednisone
Thioguanine
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed and previously untreated anaplastic large
cell Ki-1 lymphoma and T-cell large cell lymphoma Malignant lymphoblasts (identified by
immunophenotype) in pleural fluid, ascitic fluid, or bone marrow sufficient for diagnosis
Large cell lymphoma with T-cell phenotype eligible Localized mediastinal disease and bone
lymphoma eligible CNS disease eligible and defined as: Any clearly identifiable tumor cells
in cerebral spinal fluid Cranial nerve palsy (if not explained by extra cranial tumor)
Clinical Spinal Cord Compression Isolated intra cerebral mass No cranial nerve palsies
requiring immediate CNS irradiation

PATIENT CHARACTERISTICS: Age: Under 21 Performance status: Not specified Hematopoietic: Not
specified Hepatic: Not specified Renal: Not specified Cardiovascular: Shortening fraction
greater than 27% on echocardiogram (ECHO) OR Left ventricular ejection fraction greater
than 47% on radionuclide scan (RCNA) OR Cardiac function assessed as within normal limits
by cardiologist ECHO or RCNA obtained as close as clinically possible to start of therapy

PRIOR CONCURRENT THERAPY: No prior therapy except emergency treatment of airway obstruction
or superior vena cava syndrome No more than 72 hours between emergency radiotherapy or
steroids and initiation of protocol therapy